Brand name: Belsomra
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More Information on suvorexant (Belsomra)
- Statement: Another Reckless FDA Action: Approval of Suvorexant (Belsomra), August 14, 2014
- Letter to the FDA Opposing Approval of the Sleep Medicine Suvorexant, June 14, 2013
- Testimony to the FDA Peripheral and Central Nervous Systems Drugs Advisory Committee on Suvorexant, May 22, 2013